The journey of Revolution Medicines began in 2014, born from a collective passion to confront some of the most formidable challenges in cancer treatment. Headquartered in the heart of the biotech hub of Redwood City, California, the company was founded by a visionary team including Kevan Shokat, Michael Fischbach, and Martin Burke, with Mark A. Goldsmith taking the helm as CEO. Their ambitious mission from the outset was to discover and develop novel therapies for patients with RAS-addicted cancers, a group of malignancies that account for a staggering 30% of all human cancer diagnoses and have historically been notoriously difficult to treat. The founders recognized that conventional approaches had failed to effectively target the active, 'on' state of the RAS proteins that drive tumor growth, leaving a significant unmet need for countless patients.
This recognition sparked a revolutionary approach. The company pioneered its proprietary TRIPOD platform, a novel drug discovery engine designed to create therapies that can bind to and inhibit the active form of RAS. This platform became the cornerstone of their research and development efforts, enabling the creation of a deep pipeline of RAS(ON) inhibitors. The initial years were marked by intensive scientific exploration and strategic fundraising, including a pivotal Series A financing of $45 million in 2015 led by Third Rock Ventures. This early investment fueled the advancement of their discovery platform and set the stage for a series of clinical breakthroughs. As the company evolved, it continued to attract significant investment and forge strategic partnerships, steadily advancing its lead candidates through rigorous preclinical and clinical trials. Today, Revolution Medicines stands as a late-stage clinical oncology company, relentlessly pursuing its goal to transform the treatment landscape for RAS-addicted cancers and offer new hope to patients and their families.
United States only